Calcium Channel Blockers for Dysrhythmias
Calcium channel blockers (CCBs) used as antidysrhythmics work by blocking calcium from entering cardiac cells, which slows conduction through the AV node and reduces the heart's contractile force. This makes them especially useful for controlling rapid ventricular rates in supraventricular tachycardias like atrial fibrillation. Only the non-dihydropyridine CCBs, specifically verapamil and diltiazem, are used as antidysrhythmics. Dihydropyridines like nifedipine act mainly on blood vessels and don't have significant effects on cardiac conduction.
Mechanisms of Calcium Channel Blockers
CCBs block L-type calcium channels in cardiac muscle cells. Calcium influx during depolarization is what triggers muscle contraction, so blocking these channels has several downstream effects:
- Reduced contractility (negative inotropy): Less calcium enters the cell during depolarization, which weakens the force of contraction. This decreases myocardial oxygen demand.
- Slowed AV node conduction (negative dromotropy): The AV node depends heavily on calcium-driven action potentials (unlike the fast sodium channels in ventricular cells). Blocking calcium here prolongs the AV nodal refractory period, which prevents rapid atrial impulses from reaching the ventricles.
- Coronary artery dilation: CCBs relax vascular smooth muscle, widening coronary arteries and improving oxygen delivery to the myocardium.
- Reduced afterload: Vasodilation in peripheral arteries lowers the resistance the heart pumps against, further decreasing cardiac workload.
These combined effects are also why CCBs can help in hypertrophic cardiomyopathy, where reducing contractility and improving diastolic relaxation eases outflow tract obstruction.
Effects of Calcium Channel Blockers
Therapeutic uses:
- Supraventricular tachycardias (SVT): The primary antidysrhythmic indication. CCBs slow the ventricular rate in atrial fibrillation and atrial flutter by limiting how many impulses pass through the AV node. They're also effective for AV nodal reentrant tachycardia (AVNRT), where a reentry circuit loops through the AV node.
- Angina pectoris: By dilating coronary arteries and reducing oxygen demand, CCBs relieve chest pain from insufficient myocardial blood flow.
- Hypertension: Vasodilation lowers blood pressure (though this is more of a secondary use in the antidysrhythmic context).
Potential side effects:
- Hypotension from vasodilation and decreased contractility. This is the most common concern during IV administration.
- Bradycardia and heart block from excessive AV node suppression. This risk increases significantly when CCBs are combined with beta-blockers.
- Peripheral edema (especially ankles) from vasodilation and capillary fluid shifts.
- Constipation, particularly with verapamil, due to smooth muscle relaxation in the GI tract.
- Dizziness and headache from vasodilation.
High-yield point: Never give IV verapamil or diltiazem to patients with wide-complex tachycardia of unknown origin. If the rhythm is actually ventricular tachycardia (not SVT), CCBs can cause hemodynamic collapse. Also avoid these drugs in patients with Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation, as blocking the AV node can force conduction down the accessory pathway and trigger ventricular fibrillation.
Cardiac Electrophysiology and Calcium Channel Blockers
Understanding where CCBs act on the cardiac action potential helps clarify their effects:
- The SA node and AV node generate "slow-response" action potentials that depend on calcium influx (not sodium). This is why CCBs have such a pronounced effect on these structures.
- In working myocardial cells (atria and ventricles), calcium is responsible for the plateau phase (Phase 2) of the action potential. Blocking it here shortens the plateau and reduces contractile force.
- CCBs have minimal effect on Phase 0 depolarization in ventricular cells, since those cells rely on fast sodium channels. This is why CCBs don't significantly affect ventricular conduction velocity.
The net result: CCBs are negative chronotropic (slow heart rate), negative dromotropic (slow AV conduction), and negative inotropic (reduce contractility). They also cause vasodilation by acting on calcium channels in vascular smooth muscle.
Nursing Considerations for Administration
-
Assess baseline vitals and rhythm. Document blood pressure, heart rate, and a 12-lead ECG before the first dose. You need a reference point to detect changes.
-
Monitor BP and HR closely, especially with IV administration. Verapamil IV can cause rapid hypotension. Have IV calcium gluconate available as a reversal agent for severe hypotension.
-
Check for contraindications before giving the drug:
- Heart failure with reduced ejection fraction (the negative inotropic effect can worsen it)
- Second- or third-degree heart block
- Severe hypotension (systolic BP below 90 mmHg)
- Concurrent IV beta-blocker use (risk of profound bradycardia and heart block)
-
Watch for signs of excessive AV block: lengthening PR interval on the monitor, new bradycardia, or dropped beats. Be prepared for temporary transcutaneous pacing if severe bradycardia develops.
-
Administer IV formulations slowly per facility protocol. Rapid IV push of verapamil is particularly dangerous.
-
Monitor for drug interactions. Verapamil inhibits CYP3A4 and P-glycoprotein, which can raise levels of digoxin, simvastatin, and cyclosporine, among others. Check the patient's medication list carefully.
Patient Education for Calcium Channel Blockers
- How the drug works: Explain that the medication slows the heart's electrical signals at the AV node, which helps control a fast or irregular heart rate. Keep the explanation straightforward.
- Taking the medication correctly: Stress the importance of taking it at the same time each day. Extended-release tablets should never be crushed or chewed. If a dose is missed, the patient should not double up.
- Self-monitoring: Teach the patient to check their pulse daily. They should know their target heart rate range and when to call their provider (for example, if the resting heart rate drops below 50-60 bpm, depending on provider instructions).
- Side effects to report: Severe dizziness, fainting, significant ankle swelling, or feeling like the heart is beating very slowly. Constipation (especially with verapamil) can be managed with increased fiber and fluids, but persistent symptoms should be discussed with the provider.
- Avoid grapefruit juice with verapamil and diltiazem. Grapefruit inhibits CYP3A4 in the gut, which can significantly increase drug levels and the risk of toxicity.
- Lifestyle support: Regular moderate exercise, stress management, a diet low in sodium and saturated fat, and limiting alcohol all support the treatment plan.
- Follow-up: Regular appointments for ECGs and blood pressure checks help ensure the medication is working safely. Periodic lab work may be needed to monitor for drug interactions.